Global Pharmaceutical and Biotechnology Industry Boosts Confidence for Investors as the Market Expands
Companies are exploring new markets for innovative assets to add value to their pipeline, finds Frost & Sullivan
31-Jul-2015
- United Kingdom
- The rise of market demand for drugs
- Governments striving to contain drug prices
- A decline in profitability of large pharmaceutical companies
- Firms experiencing patent expiries and revenue losses
- A decline of research & development by large pharmaceutical companies
“Shrinking pipelines and increased cost pressures make mergers and acquisitions a lifeline for participants in the pharmaceuticals sector,” noted Edacherian. “Mergers and acquisitions are either approached as an exit option for investors, or as a strategy for leading pharmaceutical companies to expand their capabilities in the global market.”
Most read news
Organizations
Frost & Sullivan
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.